market access Archives - Page 8 of 51 -

AstraZeneca has said it will be able to meet a target to deliver 180 million COVID-19 vaccines to

AZ to divert COVID-19 vaccines from global supply chain to meet EU target

https://pharmaphorum.com/news/az-to-miss-q2-covid-19-vaccine/

Europe orders another 200m doses of Pfizer/BioNTech COVID shot

Richard Staines AstraZeneca, BioNTech, market access, Pfizer, vaccine 0 Comment

The European Commission has ordered another 200 million doses of the Pfizer/BioNTech COVID-19 vaccine Comirnaty, bringing the bloc’s

Europe orders another 200m doses of Pfizer/BioNTech COVID shot

https://pharmaphorum.com/news/europe-orders-another-200m-doses-of-pfizer-biontech-covid-shot/

Doctor in white rubber protective gloves putting adhesive bandage on young man's arm after scratch on skin or injection of vaccine. First aid. Medical, pharmacy and healthcare concept. Closeup.

Market Access/ News/ News

UK government mulls lockdown review as it hits 15m COVID vaccine target

Richard Staines COVID-19, infectious diseases, lockdown, market access, vaccine 0 Comment

More than 15 million people in the UK have had their first coronavirus vaccine, described as a ‘significant

UK government mulls lockdown review as it hits 15m COVID vaccine target

https://pharmaphorum.com/news/uk-mulls-lockdown-review-as-it-hits-15m-covid-vaccine-target/

Market Access/ News/ News

BMS’ MS pill gets funding in Scotland after rejection in England by NICE

Richard Staines cost-effectiveness, market access, multiple sclerosis, neurology, SMC 0 Comment

Scotland’s drugs cost-effectiveness body has recommended Bristol-Myers Squibb’s Zeposia multiple sclerosis pill, setting a potential north-south access divide

BMS’ MS pill gets funding in Scotland after rejection in England by NICE

https://pharmaphorum.com/news/bms-ms-pill-gets-funding-in-scotland-after-rejection-in-england-by-nice/

Market Access/ News/ News

NICE backs NHS funding for MSD’s Keytruda combination in lung cancer

Richard Staines Keytruda, lung cancer, market access, Merck & Co, NICE 0 Comment

NICE has backed regular NHS funding England and Wales for Merck, Sharp and Dohme’s Keytruda in combination with

NICE backs NHS funding for MSD’s Keytruda combination in lung cancer

https://pharmaphorum.com/news/nice-backs-nhs-funding-for-msds-keytruda/

Market Access/ News/ News

UK patient group warns COVID could limit access to Novartis’ new eye drug

Richard Staines Bayer, Beovu, market access, NICE, Novartis, ophthalmology, Regeneron 0 Comment

NICE has recommended regular NHS funding for Novartis’ long-acting eye drug Beovu (brolucizumab) in England and Wales –

UK patient group warns COVID could limit access to Novartis’ new eye drug

https://pharmaphorum.com/news/patient-group-warns-covid-limit-access-novartis-eye-drug/

Market Access/ Views & Analysis/ Views and analysis

2021 market access prospects for Italy

Leela Barham EU market access, Italian Medicines Agency, Italy, market access, pricing, reimbursement 0 Comment

Italy was working up big changes in market access throughout 2020 which will be implemented in 2021. In

2021 market access prospects for Italy

https://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-italy/

Market Access/ News/ News

NICE rejects BMS’ Zeposia MS pill in provisional guidance

Richard Staines Bristol-Myers Squibb, cost-effectiveness, market access, multiple sclerosis, Roche, Zeposia 0 Comment

NICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing

NICE rejects BMS’ Zeposia MS pill in provisional guidance

https://pharmaphorum.com/market-access-2/nice-rejects-bms-zeposia-ms-pill-in-provisional-guidance/

Market Access/ News/ News

NHS and Kite sign access deal for Kite’s cancer cell therapy Tecartus

Richard Staines CAR T, Gilead, Kite, lymphoma, market access, NICE, Oncology, Tecartus 0 Comment

NHS patients in England will be among the first in the world to receive Gilead’s Tecartus cancer cell

NHS and Kite sign access deal for Kite’s cancer cell therapy Tecartus

https://pharmaphorum.com/news/nhs-kite-cancer-therapy/

Trending

market access

Login